Showing 7461-7470 of 8892 results for "".
- Zilxi from Vyne Therapeutics Now Availablehttps://practicaldermatology.com/news/zilxi-from-vyne-therapeutics-now-available/2460551/Zilxi™ (minocycline) topical foam, 1.5% is now available by prescription for the treatment of inflammatory lesions of rosacea in adults. Zilxi, from Vyne Therapeutics, Inc. is the first minocycline product of any form to be approved by the FDA for use in rosacea, a diverse skin co
- With Label Extension, Simponi Aria Approved for PsA in Kids as Young as Twohttps://practicaldermatology.com/news/with-label-extension-simponi-aria-approved-for-psa-in-kids-as-young-as-two/2460549/The FDA has approved Simponi Aria (golimumab) for the treatment of active pJIA for patients two years of age and older and has extended the PsA indication for this same patient population. In Phase 3 clinical trials with pediatric patients, pharmacokinetic (PK) exposure of
- FemiClear for Genital Herpes Symptoms Launcheshttps://practicaldermatology.com/news/femiclear-for-genital-herpes-symptoms-launches/2460547/FemiClear brand has released new FemiClear for Genital Herpes Symptoms to relieve the symptoms of genital herpes outbreaks. This new product, backed by both an in vitroand in vivostudy, is now available at CVS stores nationwide. New
- Practical Dermatology® magazine, Modern Aesthetics® magazine Recognized For Excellence by Folio: Magazinehttps://practicaldermatology.com/news/practical-dermatology-magazine-modern-aesthetics-magazine-recognized-for-excellence-by-folio-magazine/2460546/Bryn Mawr Communications III, LLC is pleased to announce that Practical Dermatology® magazine and sister publication Modern Aesthetics® magazine took home two Honorable Mentions from Folio: Magazine’s 2020 Eddie & Ozzie Awards, including a nod for Editorial Tea
- NEA Shares Educational Resources for October's Eczema Awareness Monthhttps://practicaldermatology.com/news/nea-shares-educational-resources-for-octobers-eczema-awareness-month/2460545/The National Eczema Association (NEA) is offering a robust series of virtual educational programs, patient/caregiver support experiences, community engagement activities and free resources throughout October's Eczema Awareness Month This year's month-long stakeholder engagement
- Topical PDE4 Inhibitor from Arcutis Shows Benefit in Seborrheic Dermatitishttps://practicaldermatology.com/news/topical-pde4-inhibitor-from-arcutis-shows-benefit-in-seborrheic-dermatitis/2460544/Positive topline data from a Phase 2 clinical trial suggest ARQ-154 (topical roflumilast foam) from Arcutis Biotherapeutics, Inc. is a potential treatment for seborrheic dermatitis. Study results show that roflumilast foam 0.3%
- Tattoos Impair Sweating, May Increase Risk of Heat-related Injuryhttps://practicaldermatology.com/news/tattoos-impair-sweating-may-increase-risk-of-heat-related-injury/2460539/New research finds that tattooed skin does not sweat as much as non-inked areas, which may have implications for the body’s ability to cool in people with extensive tattooing.
- Hoth Therapeutics’ HT-003 Inhibits Acne Gene TLR2https://practicaldermatology.com/news/hoth-therapeutics-ht-003-inhibits-acne-gene-tlr2/2460538/Hoth Therapeutics, Inc. completed testing on the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes. Initial data from the first phase of the research reports that toll-like receptor 2 (TLR2) is significantly
- Suneva to Market and Distribute Neauvia's Plasma IQ in North Americahttps://practicaldermatology.com/news/suneva-to-market-and-distribute-neauvias-plasma-iq-in-north-america/2460534/Suneva Medical, Inc., will market and distribute Neauvia Plasma IQ throughout North America as part of a new partnership. The first Class 2 FDA-cleared plasma energy device, Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing
- Medimetriks Streamlines MM36 AD Development Programhttps://practicaldermatology.com/news/medimetriks-streamlines-mm36-ad-development-program/2460532/Medimetriks Pharmaceuticals, Inc. is moving forward with its MM36 (difamilast) Atopic Dermatitis Development Program following a meeting with the U.S. Food and Drug Administration (FDA). Medimetriks is now preparing to conduct a s